SLE patients with an IFN signature could benefit from a human anti-IFN Ab, which competes with IFN-α binding to the receptor IFNAR2, thus preventing the activation of the IFN-α mediated pathways [150]. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.